Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY(2022)
摘要
There is a paucity of treatment options for patients who have failed multiple biologics. A drawback of biologic therapies is their selectivity in targeting a single pathway. We report the use of dual biologic therapy with vedolizumab and ustekinumab for three highly refractory patients who previously failed both of these medications as monotherapy. The dual biologic therapy led to the closure of a recto-vaginal fistula and restoration of continuity after takedown of a stoma.
更多查看译文
关键词
Crohn's disease, dual biologic therapy, multidrug refractory Crohn's
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要